Abstract
Ximelagatran is an oral direct thrombin inhibitor (DTI), the active form of which is melagatran. Approximately 20% of an oral ximelagatran dose becomes bioavailable as melagatran, which binds noncovalently and reversibly to both fibrin-bound and freely circulating thrombin. Oral ximelagatran dosing not only inhibits thrombin activity rapidly, competitively, and potently, but also delays and suppresses thrombin generation. In humans, oral ximelagatran exhibits anticoagulant, antiplatelet, and profibrinolytic effects, with only minor prolongation of the capillary bleeding time. Oral ximelagatran exhibits a stable and predictable pharmacokinetic profile during repeated dosing, with low intra- and inter-individual variation, and a low potential for interaction with other medications. It is excreted primarily as melagatran via the kidney, without unexpected bioaccumulation. Dosing requirements do not vary with age, gender, ethnicity, obesity, or food or alcohol intake. Clinical trials (total n > 30,000) have evaluated oral ximelagatran in four indications: the prevention of venous thromboembolism (VTE, comprising deep venous thrombosis with or without and pulmonary embolism) after elective hip- or knee-replacement surgery (with approval granted by France, as the Reference Member State for the European Union); treatment and long-term secondary prevention of VTE; the prevention of stroke and other systemic embolic events associated with nonvalvular atrial fibrillation; and the prevention of cardiovascular events after an acute myocardial infarction. The results of these trials suggest that the benefit-risk profile of oral ximelagatran therapy, administered at a fixed-dose without coagulation monitoring, compares favorably with that of currently approved standard therapy.
Keywords: ximelagatran, melagatran, direct thrombin inhibitors, anticoagulation, antithrombotic agents, oral administration, thromboembolism
Current Pharmaceutical Design
Title: Ximelagatran - A Promising New Drug in Thromboembolic Disorders
Volume: 11 Issue: 4
Author(s): Palle Petersen
Affiliation:
Keywords: ximelagatran, melagatran, direct thrombin inhibitors, anticoagulation, antithrombotic agents, oral administration, thromboembolism
Abstract: Ximelagatran is an oral direct thrombin inhibitor (DTI), the active form of which is melagatran. Approximately 20% of an oral ximelagatran dose becomes bioavailable as melagatran, which binds noncovalently and reversibly to both fibrin-bound and freely circulating thrombin. Oral ximelagatran dosing not only inhibits thrombin activity rapidly, competitively, and potently, but also delays and suppresses thrombin generation. In humans, oral ximelagatran exhibits anticoagulant, antiplatelet, and profibrinolytic effects, with only minor prolongation of the capillary bleeding time. Oral ximelagatran exhibits a stable and predictable pharmacokinetic profile during repeated dosing, with low intra- and inter-individual variation, and a low potential for interaction with other medications. It is excreted primarily as melagatran via the kidney, without unexpected bioaccumulation. Dosing requirements do not vary with age, gender, ethnicity, obesity, or food or alcohol intake. Clinical trials (total n > 30,000) have evaluated oral ximelagatran in four indications: the prevention of venous thromboembolism (VTE, comprising deep venous thrombosis with or without and pulmonary embolism) after elective hip- or knee-replacement surgery (with approval granted by France, as the Reference Member State for the European Union); treatment and long-term secondary prevention of VTE; the prevention of stroke and other systemic embolic events associated with nonvalvular atrial fibrillation; and the prevention of cardiovascular events after an acute myocardial infarction. The results of these trials suggest that the benefit-risk profile of oral ximelagatran therapy, administered at a fixed-dose without coagulation monitoring, compares favorably with that of currently approved standard therapy.
Export Options
About this article
Cite this article as:
Petersen Palle, Ximelagatran - A Promising New Drug in Thromboembolic Disorders, Current Pharmaceutical Design 2005; 11 (4) . https://dx.doi.org/10.2174/1381612053382016
DOI https://dx.doi.org/10.2174/1381612053382016 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Streptokinase as a Virulence Determinant of Streptococcus pyogenes – Potential for Therapeutic Targeting
Current Drug Targets Thyroid Hormone Ligands and Metabolic Diseases
Current Pharmaceutical Design A Box-Behnken Optimized Methodology for the Quantification of Diclofenac using a Carbon Paste-Multiwalled Carbon Nanotubes Electrode
Current Analytical Chemistry Thiazolidinediones and Cardiovascular Risk — A Question of Balance
Current Cardiology Reviews Morphological and Molecular Changes of the Myocardium After Left Ventricular Mechanical Support
Current Cardiology Reviews Secondary Stroke Prevention in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Vascular Disease Prevention (Discontinued) Food and Food Supplements with Hypocholesterolemic Effects
Recent Patents on Food, Nutrition & Agriculture Genetic Studies of Type 2 Diabetes in South Asians: A Systematic Overview
Current Diabetes Reviews Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets Profile of IKs During the Action Potential Questions the Therapeutic Value of IKs Blockade
Current Medicinal Chemistry Foods and Drugs in the Management of Disease: A Case Study Comparing Omega-3 Fatty Acids and Aspirin for Inflammation
Current Pediatric Reviews Pulmonary Hypertension secondary to Left Heart Disease
Current Vascular Pharmacology Inhibition of Major Drug Metabolizing CYPs by Common Herbal Medicines used by HIV/AIDS Patients in Africa– Implications for Herb- Drug Interactions
Drug Metabolism Letters Knowing is Half the Battle: Targeting Virulence Factors of Group A Streptococcus for Vaccine and Therapeutics
Current Drug Targets Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Current Pharmaceutical Design Graphical Abstracts
Inflammation & Allergy - Drug Targets (Discontinued) Bergamot Juice Extract Inhibits Proliferation by Inducing Apoptosis in Human Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach
Current Medicinal Chemistry Alzheimer’s Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome
Current Neuropharmacology